SCHEMBL23625903

SCHEMBL23625903

CC(C)(O)c1nc2cc3c(cc2cc1N)OCO3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.37
ALDH1A1 P00352 5/20 0.37
MAPT P10636 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
HSD17B10 Q99714 4/20 0.37
KMT2A Q03164 4/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 3/20 0.37
TSHR P16473 3/20 0.37
TP53 P04637 2/20 0.37
MEN1 O00255 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 6/20 0.36
TDP1 Q9NUW8 3/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30952889 1.00 RAB9A (0.37) RAB9AALDH1A1MAPTSMN1; SMN2HSD17B10
SCHEMBL17942752 0.81 ULK1 (0.39) RAB9AALDH1A1MAPTSMN1; SMN2HSD17B10
SCHEMBL24823317 0.80 DYRK1A (0.37) RAB9AMAPTSMN1; SMN2KDM4ENPC1
SCHEMBL30310926 0.80 DYRK1A (0.37) RAB9AMAPTSMN1; SMN2KDM4ENPC1
SCHEMBL24823318 0.80 DYRK1A (0.37) RAB9AMAPTSMN1; SMN2KDM4ENPC1
SCHEMBL30310938 0.80 DYRK1A (0.37) RAB9AMAPTSMN1; SMN2KDM4ENPC1
SCHEMBL24823307 0.79 PDE10A (0.32)
SCHEMBL31391624 0.79 PDE10A (0.32)
SCHEMBL30148370 0.76 CYP11B1 (0.39) KMT2AMEN1TDP1L3MBTL1RXFP1
SCHEMBL24823325 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230021669-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) 2023-01-26 US disclosed
WO-2021136244-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230021669-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF CYP4A11, CYP4F11, CYP11B2 RAB9A 4325/4885ALDH1A1 50/4885MAPT 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.